200 results on '"Wakui, Hiroshi"'
Search Results
2. Stability of constant steady states of a chemotaxis model
3. Large self-similar solutions of the parabolic-elliptic Keller--Segel model
4. Finite time blow up and concentration phenomena for a solution to drift-diffusion equations in higher dimensions
5. PRKN-regulated mitophagy and cellular senescence during COPD pathogenesis
6. Supplementary Table S6 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)
7. Data from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)
8. Supplementary Figure S2 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)
9. Phase II study of durvalumab immediately after completion of chemoradiotherapy in unresectable stage III non–small-cell lung cancer: TORG1937 (DATE study)
10. A Phase Ⅱ Study of Ubenimex Combined With Pembrolizumab, Nab-Paclitaxel, and Carboplatin for Previously Untreated Advanced Squamous Non–Small-Cell Lung Cancer: TORG2241 (UBE-Q)
11. Successful treatment of steroid-refractory immune checkpoint inhibitor-related pneumonitis with triple combination therapy: a case report
12. Reconsidering the Cutoff Value for Sensitive and Refractory Relapses in Extensive-Stage SCLC in the Era of Immunotherapy
13. Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non–Small-cell Lung Cancer
14. Unboundedness for solutions to a degenerate drift-diffusion equation with the L1-supercritical and the energy subcritical exponent
15. Finite time blow up and non-uniform bound for solutions to a degenerate drift-diffusion equation with the mass critical exponent under non-weight condition
16. The rate of concentration for the radially symmetric solution to a degenerate drift-diffusion equation with the mass critical exponent
17. Increased levels of prostaglandin E−major urinary metabolite (PGE-MUM) in chronic fibrosing interstitial pneumonia
18. First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations: The UNICORN Phase 2 Nonrandomized Clinical Trial.
19. Fibroblast-Derived Extracellular Vesicles Induce Lung Cancer Progression in the IPF Microenvironment
20. Involvement of cigarette smoke-induced epithelial cell ferroptosis in COPD pathogenesis
21. Exploratory analysis to predict pneumonitis during durvalumab consolidation therapy for patients with locally advanced non‐small cell lung cancer from proteomic profiling of circulating extracellular vesicles.
22. Finite time blow up and concentration phenomena for a solution to drift-diffusion equations in higher dimensions
23. 気管支喘息発作との鑑別が困難であった気道限局型M.abscessus subsp. massilience症の1例
24. Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors
25. Risk factors of moderate-to-severe exacerbation in patients with chronic obstructive pulmonary disease (Original)
26. Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with advanced solid tumors
27. A phase 1 study of lenvatinib, multiple receptor tyrosine kinase inhibitor, in Japanese patients with advanced solid tumors
28. A phase II study of durvalumab (MEDI4736) immediately after completion of chemoradiotherapy in unresectable stage III non–small cell lung cancer: TORG1937 (DATE study).
29. Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer
30. Phase I study of the anti-MET antibody onartuzumab in patients with solid tumors and MET-positive lung cancer
31. Phase I and pharmacokinetics/pharmacodynamics study of the MEK inhibitor RO4987655 in Japanese patients with advanced solid tumors
32. Possible relationship between esophageal dilatation and severity of M. abscessus pulmonary disease
33. A phase 1 and dose-finding study of LY2523355 (litronesib), an Eg5 inhibitor, in Japanese patients with advanced solid tumors
34. Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors
35. Stability of constant steady states of a chemotaxis model
36. Impaired TRIM16-Mediated Lysophagy in Chronic Obstructive Pulmonary Disease Pathogenesis
37. Short Hydration in Chemotherapy Containing Cisplatin (≥75 mg/m2) for Patients with Lung Cancer: A Prospective Study
38. Uncommon mutations conducted with osimertinib in patients with NSCLC: a study protocol of phase 2 study (UNICORN/TCOG1901).
39. Dasatinib-induced Nonspecific Interstitial Pneumonia That Developed 7 Years after the Initiation of Dasatinib
40. Chaperone-Mediated Autophagy Suppresses Apoptosis via Regulation of the Unfolded Protein Response during Chronic Obstructive Pulmonary Disease Pathogenesis
41. Existence of solutions to a one-dimensional Hamilton–Jacobi equation with a degenerate Hamiltonian
42. Association of High Neutrophil-to-Lymphocyte Ratio With Poor Outcomes of Pembrolizumab Therapy in High-PD-L1-expressing Non-small Cell Lung Cancer
43. Involvement of GPx4-Regulated Lipid Peroxidation in Idiopathic Pulmonary Fibrosis Pathogenesis
44. Lysosomal dysfunction in COPD pathogenesis
45. Prostaglandin E-Major Urinary Metabolite (PGE-MUM) as a Tumor Marker for Lung Adenocarcinoma
46. Involvement of Lamin B1 Reduction in Accelerated Cellular Senescence during Chronic Obstructive Pulmonary Disease Pathogenesis
47. 鉄依存性細胞死フェロトーシスのCOPD病態への関与 (第134回成医会総会一般演題)
48. PRKN-regulated mitophagy and cellular senescence during COPD pathogenesis
49. Dysregulated mitochondrial integrity associated with lamin B1 reduction is involved in cellular senescence progression in COPD pathogenesis
50. Risk factors of postoperative pulmonary complications in patients with asthma and COPD
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.